Quote | Can-Fite Biopharma Ltd Sponsored ADR (NYSE:CANF)
|Last Trade Date Time:||05/26/2023 03:00:00 am|
News | Can-Fite Biopharma Ltd Sponsored ADR (NYSE:CANF)
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer, and liver diseases, today announced its VP of Business Development, Dr. Sari Fishman, will participate in BioEquity Eur...
Exploratory, small, open-label study aims to assess potential efficacy of Namodenoson following strong preclinical results in pancreatic cancer Namodenoson, now in a pivotal Phase 3 liver cancer study, has completely cleared liver cancer in a patient who remains cancer-free 6 years af...
Message Board Posts | Can-Fite Biopharma Ltd Sponsored ADR (NYSE:CANF)
|A complete and total fluff||midastouch017||investorshub||04/24/2023 12:02:45 PM|
|Can-Fite Announces New Management Structure as Advanced Stage||midastouch017||investorshub||04/24/2023 11:55:17 AM|
|Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal||midastouch017||investorshub||04/10/2023 12:34:40 PM|
|Dr. Sari Fishman, the Companys Vice President of||midastouch017||investorshub||03/30/2023 12:06:50 PM|
|Revenues for the year ended December 31, 2022||midastouch017||investorshub||03/30/2023 11:59:37 AM|